SETD7 (SET Domain Containing 7)

Activation of autophagy by rapamycin (Rapa) effectively rescued the BMSCs osteogenic differentiation reduced by HQ. Collectively, these findings indicated that SETD7 promoted osteogenic differentiation in HQ-exposed BMSCs via autophagy-dependent mechanism. This study provides mechanistic insight into how HQ may disrupt the bone marrow microenvironment, highlights the role of SETD7 in maintaining osteogenic differentiation and autophagy in HQ-exposed BMSCs, and contributes to a better understanding of the epigenetic and cellular pathways involved in HQ-induced hematotoxicity.

Gαi1 promotes tumor progression in NPC through the cell cycle, ERK and Akt-mTOR pathway and by regulating SETD7. Targeting Gαi1 or its signaling may offer a novel therapeutic strategy for NPC and potentially other cancers.

Based on receiver operating characteristic (ROC) analysis, increased SETD7 gene expression can be used as a good biomarker to distinguish tumor tissue from normal tissue in the early stages (area under the ROC curve = 0.85). Increased SETD7 gene expression can be used as an epigenetic marker in tissue-based prognosis and screening of CRC in the early tumor stages.

The study reveals that TIPE3 is epigenetically regulated by enhancer elements, which are modulated by KAT2A and SETD7, and that TIPE3 promotes NPC progression through activation of the Hedgehog signaling pathway. These findings suggest that targeting the enhancer-mediated regulation of TIPE3 and the associated signaling pathways could offer new therapeutic strategies for NPC.

Schematic diagram illustrating the mechanism by which SETD7 accelerates ESCC progression through enhancing ferroptosis resistance. Created with BioRender.

This review comprehensively explores SETD7's structure, subcellular localization, and diverse biological functions in both normal and disease states. By elucidating the dual and context-dependent nature of SETD7, it aims to provide a framework for future research focused on unraveling its molecular mechanisms and advancing targeted therapeutic approaches that leverage its unique regulatory capabilities.

In this review, we focus on the involvement of SETD7 in the hallmarks of cancer, describing its functions and underlying mechanisms in detail. Additionally, we discuss non-coding RNAs and chemical inhibitors targeting SETD7, highlighting the potential and importance of SETD7 in cancer therapy.

In addition, CHAF1B competitively binds to the SETD7 promoter region and represses its transcription. Altogether, these results imply that CHAF1B plays a vital role in LUSC tumorigenesis and may represent a potential molecular target for this deadly disease.

SETD7 plays a critical role in the pathogenesis of OA by modulating chondrocyte survival, apoptosis, inflammation, and autophagy. The interaction between YTHDF2 and SETD7 exacerbates chondrocyte injury under inflammatory conditions, highlighting potential therapeutic targets for OA treatment. The YTHDF2/SETD7 axis offers a novel insight into the molecular mechanisms governing cartilage degeneration in OA.

miR-330-5p targeted SETD7, and SETD7 upregulation blocked the therapeutic effect of MSCs-Exo-derived miR-330-5p on MCAO rats. MSCs-Exo-derived miR-330-5p targets SETD7 to reduce inflammation in MCAO rats, providing a new therapeutic target for CI/RI therapy.

Furthermore, SETD7 exerts a tumor-promotive function in ovarian cancer (OC) cells in a K51 methylation-dependent manner. Collectively, our data define a novel modification of LC3B and highlight the oncogenic effect of SETD7 via mediating LC3B methylation and degradation.

Therefore, the non-accessibility of the histone methyltransferase activity domain of SET7 with IMPHY002979 can downregulate H3K4me1 and, thereby, the expression of genes potentially responsible for immunosuppressive TME. Thus, patient stratification based on molecular markers for immunotherapy and combining epigenetic modulators with therapeutic drugs will improve the efficacy of immunotherapy in ccRCC.